Virpax Pharmaceuticals Inc (VRPX) - Total Assets
Based on the latest financial reports, Virpax Pharmaceuticals Inc (VRPX) holds total assets worth $1.56 Million USD as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Virpax Pharmaceuticals Inc - Total Assets Trend (2018–2024)
This chart illustrates how Virpax Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Virpax Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
Virpax Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Virpax Pharmaceuticals Inc's total assets of $1.56 Million consist of 100.0% current assets and 0.0% non-current assets. Review total liabilities of Virpax Pharmaceuticals Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Virpax Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Virpax Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Virpax Pharmaceuticals Inc's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2024, down from 78.7% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Virpax Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Virpax Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Virpax Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.63 | 1.25 | 0.01 |
| Quick Ratio | 0.63 | 1.25 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-913.76K | $1.93 Million | $-3.50 Million |
Virpax Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Virpax Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.48 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 16056.6% |
| Total Assets | $1.56 Billion |
| Market Capitalization | $273.35K USD |
Valuation Analysis
Below Book Valuation: The market values Virpax Pharmaceuticals Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Virpax Pharmaceuticals Inc's assets grew by 16056.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Virpax Pharmaceuticals Inc (2018–2024)
The table below shows the annual total assets of Virpax Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.56 Billion | +16056.61% |
| 2023-12-31 | $9.63 Million | -51.06% |
| 2022-12-31 | $19.67 Million | -50.28% |
| 2021-12-31 | $39.57 Million | +8402.78% |
| 2020-12-31 | $465.41K | +896.18% |
| 2019-12-31 | $46.72K | -24.03% |
| 2018-12-31 | $61.50K | -- |
About Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an … Read more